Assessment of the effects of whey protein on psoriasis

Phase 2

• Conditions: Psoriasis.; Plaque psoriasis

• Registration Number: IRCT2015100524359N1
• Lead Sponsor: Tehran University of Medical Science

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

patients above 18 years old ;skin involvement under 10 percent ;stable plaque psoriasis (which have been stable in extent and severity for at least 2 months) ; patients who haven’t been using psoralen for the past 28 days and UVB for the past 30 days ; patients who haven’t participated in any studies in the last month;patients who consent on participating in the study.
The criteria that impede patients from entering the study : age under 18 and above 70 years old ;Patients suffering from other kinds of psoriasis like pustular, erythrodermic, or palmoplantar or psoriatic arthritis or patient having their face involved;skin involvement more than 10 percent ; past history of allergy to lactose ;patients suffering from the kidney stone disease; patients who use drugs that intensify psoriasis e.g.Beta blockers ?NSAIDs?Antimalarials ?Terbinafine?Ca channel blockers?Interleukins and Lithium ;Oral corticosteroids or immunosuppressants consumption during the 4 weeks prior to baseline ;pregnancy and lactation ;The patients suffering from uncontrolled cardiovascular and respiratory and hematological and urinary diseases ;those who have known cancer and cancer history in the last 5 years? those have metabolic diseases and water and electrical imbalance and infection; any record of allergy ; acute sensitivity and progressive form of disease and tendency to erythrodermy ;patients who must use systemic psoriasis drugs; patients are dissatisfaction with participating in the study .
The criteria that lead to the exclusion of the patients who were participating in the study :
skin events after taking the drug during the study ; infection on the lesion during the study ; patients getting pregnant during the study ; patient suffering from the kidney stone disease during the study.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity. Timepoint: At baseline -end of 8 and 12 weeks. Method of measurement: psoriasis activity and severity index.;Extent of the lesion. Timepoint: At baseline -end of 8 and 12 weeks. Method of measurement: BODY SURFACE AREA.;Quality of life. Timepoint: At baseline -end of 12 weeks. Method of measurement: persian valid version of Dermatology of life and quality index.;Intensity of pruritis. Timepoint: At baseline -end of 8 and 12 weeks. Method of measurement: VISUAL analog Scale.

Secondary Outcome Measures

Name	Time	Method
Evaluation of Possibe gastrointestinal and skin complications. Timepoint: End of 8 and 12 weeks. Method of measurement: CTCAE) common terminology for Adverse Event v40.2009).;The photography of lesion. Timepoint: At baseline-end of 8 and 12 weeks. Method of measurement: The camera with 10 mega pixel sensor accuracy specifications .Canon EOS 400D Lens EFS18-55mm.